Capricor Therapeutics (CAPR) FDA announcement summary
Event summary combining transcript, slides, and related documents.
FDA announcement summary
21 Nov, 2026Introduction and purpose
Regulatory update on the resubmitted Deramiocel BLA for Duchenne muscular dystrophy (DMD).
Details of approval or decision
FDA issued a Complete Response Letter (CRL), finding the data insufficient to establish substantial evidence of effectiveness and citing other clinical deficiencies.
Impact on industry and stakeholders
The CRL prompted an expression of disappointment for people living with DMD and their families.
As of Sept. 30, 2026, cash, cash equivalents, restricted cash and marketable securities totaled ~$198.5 million, believed sufficient for at least 12 months of planned operations.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Capricor Therapeutics
- FDA uncertainty contrasts with HOPE-3’s positive endpoint as losses widen.CAPR
Q3 2026 - HOPE-3 success advances Deramiocel toward a pivotal FDA decision in DMD.CAPR
Corporate presentation - HOPE-3 and pooled analyses showed Deramiocel preserved upper-limb function.CAPR
Study result - FDA review ongoing for deramiocel; Q2 net loss $40.7M, new HQ lease tied to approval.CAPR
Q2 2026 - Deramiocel advances toward approval and commercial launch, backed by strong clinical data.CAPR
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Lead DMD therapy met Phase 3 endpoints, with FDA review underway and global expansion planned.CAPR
Corporate presentation - FDA review for Deramiocel advances as losses rise and legal, commercial efforts intensify.CAPR
Q1 2026 - BLA for deramiocel advances with strong data, $86M funding, and global expansion plans.CAPR
Q3 2024 - Q1 net loss was $24.4M as deramiocel advances under FDA review and cash reserves remain strong.CAPR
Q1 2025